# GPT-5-mini Review

**Role:** External referee review
**Model:** openai/gpt-5-mini
**Paper:** paper.pdf
**Timestamp:** 2026-02-04T03:42:15.030927
**Route:** OpenRouter + LaTeX
**Review mode:** Tri-model (3 independent reviewers)
**Tokens:** 20605 in / 5568 out
**Response SHA256:** fac5317fa10b8c4b

---

Thank you for the opportunity to review this manuscript. The paper addresses an important policy question—do state insulin copay cap laws reduce diabetes mortality among working-age adults?—using staggered DiD methods and an understandable motivation (outcome dilution in all-ages data). The empirical approach is thoughtful and the authors implement modern staggered-DiD estimators (Callaway–Sant’Anna, Sun–Abraham), sensitivity checks (HonestDiD), placebo outcomes, and a number of robustness tests. That said, several substantive and format issues must be addressed before this paper is suitable for a top general-interest journal. I summarize detailed comments below organized under the requested headings. Where I cite “sections” I refer to the labeled sections in the LaTeX source you provided.

Short overall verdict: the empirical design is promising and the paper is potentially publishable, but important methodological/documentation gaps, data issues, and write-up problems require substantial revision. I recommend MAJOR REVISION.

1. FORMAT CHECK (must be fixed before resubmission)
- Length: The LaTeX source is long and contains a substantial appendix. Judging from the main text and extensive appendices and tables, I estimate the manuscript (main text excluding references and appendices) is plausibly ≥ 25 pages. The author should explicitly state the page count in resubmission and ensure the main text (without online appendices) is sized appropriately for the target journal. If the intended submission is to AER/QJE/JPE, the main text should be tight and the online appendix used for extended material.
- References: The source calls \bibliography{references}, but the actual .bib entries are not included in the uploaded source you provided. In the PDF this will matter. The paper cites many relevant papers (Callaway & Sant’Anna, Goodman-Bacon, Sun & Abraham, Rambachan, DCCT/EDIC, Bertrand et al., etc.), but I cannot verify the bibliography coverage because the references file is missing. Please include the full bibliographic list in the submission. I also note some important methodological and application papers are missing (see Section 4 below) and should be cited.
- Prose: Major sections (Introduction, Institutional Background, Conceptual Framework, Data, Empirical Strategy, Results, Discussion, Conclusion) are written in paragraph form—not bullets. This is good and meets the journal requirement.
- Section depth: Most major sections are substantial. The Introduction alone spans several paragraphs and contains motivation, summary of results, and contribution. Data (Section 4), Empirical Strategy (Section 5), Results (Section 6), and Discussion (Section 7) are long and detailed. That said, some subsections (e.g., certain items in robustness) compress many checks into single paragraphs—expand key robustness discussions into 3+ substantive paragraphs if possible so readers can digest the logic and results.
- Figures: Figures are included via external files (figures/*.pdf). In the LaTeX source each figure has a caption and notes. Because I do not have access to the rendered PDF images, I cannot verify axis labels, tick marks, fonts, or whether all axes show units. The authors must ensure all figures: (i) have clearly labeled axes (variable name and units), (ii) legible fonts for journal publication, (iii) include sample sizes (N) where relevant or note how many states/year observations contribute to each point in event studies, and (iv) include informative figure notes explaining data sources and estimation method. In particular: event-study graphs must show the number of treated states at each event time or a table that makes clear which cohorts contribute to each event time.
- Tables: The source inputs many tables from external files (tables/*.tex). The LaTeX appears to expect real numbers and standard errors. Again, I cannot verify the actual numbers here, but the main text reports coefficients, SEs, CIs and p-values. Ensure that every regression/table cell includes SEs or CIs in parentheses, and that each table includes N (observations), number of clusters (states), and any weighting. Also include exact specification notes (controls, trends, fixed-effects) under each table. Avoid placeholders.

2. STATISTICAL METHODOLOGY (CRITICAL)
A paper cannot pass review without proper statistical inference. I evaluate the manuscript on the checklist you provided. The good news is that the authors have implemented many best practices. But some important items are missing or require clarification/documentation.

a) Standard errors: The manuscript reports SEs and CIs for main estimates in the text (examples: TWFE SE = 1.115, CS-DiD SE = 0.744) and discusses cluster-robust SEs, CR2 corrections, and wild cluster bootstrap. This is good. However:
- Every coefficient in every regression/table must include SEs (or 95% CIs) in parentheses below the coefficient; do not leave any coefficients without inference. I could not validate all tables (external files). Fix any table that omits SEs.
- For DiD/event-study plots, include pointwise 95% CIs and report joint pre-trend test p-values in a table (not just in text) with exact p-values.

b) Significance testing: The manuscript conducts inference tests (bootstrap, CR2, wild cluster bootstrap). That is appropriate. The wild cluster bootstrap details need to be reported in tables/notes (number of bootstrap repetitions, Webb weights or Rademacher, etc.). The text sometimes reports p = 0.044 for a cohort—report exact two-sided p-values and clarify whether bootstrap p-values or asymptotic p-values are being used.

c) Confidence intervals: The main results show 95% CIs in the text. Ensure all main estimates, event-study aggregates, heterogeneity cells, and MDEs display 95% CIs. For the HonestDiD/FLCI outputs, clearly label these as “honest” confidence intervals and explain the assumptions.

d) Sample sizes: N and number of clusters must be reported for every regression. The LaTeX mentions N = 1,142 and clusters = 50 in a figure note, which is good. But ensure every regression table includes:
- Observations (state-year cells used)
- Number of states (clusters)
- Number of treated states (and treated cohorts) used in that specification
- For event-time bins, report how many treated states contribute to each event bin (especially near long leads/lags where sample falls).

e) DiD with staggered adoption: PASS. The paper uses Callaway & Sant’Anna (2021) as the primary estimator and Sun & Abraham (2021) as a robustness check. The manuscript also reports Goodman–Bacon decomposition and notes TWFE comparisons. These are the correct steps for staggered adoption. A few clarifications required:
- The authors reclassify not-yet-treated states (treatment onset > sample end) as never-treated. They note this produces identical estimates because these states have no post-treatment observations in sample. That is correct in many implementations, but the text must explicitly explain the identifying logic and note limitations; provide code or replicable explanation that the did package was used with first_treat = 0 for these states. Also list which states were reclassified (the table does, but be explicit).
- Provide results using never-treated states only (excluding not-yet-treated) as an additional robustness specification. This addresses concerns about potential contamination if not-yet-treated states are systematically different.
- For CS-DiD: report group-time ATTs for each cohort in a table (you have cohort ATTs in appendix but ensure they are present and interpretable) and show weights used in aggregation.

f) RDD: Not applicable. (No RDD in paper.) If RDD methods are mentioned in literature review, ensure the Imbens & Lemieux and Lee & Lemieux references are present (see Section 4).

Critical failure clause: The paper would be immediately unpublishable if any main coefficient lacked standard errors, if no inference tests were provided, or if TWFE only (no modern DiD corrections) were the only method with staggered adoption. The authors have avoided that fatal problem. Still, to be acceptable, the paper must:
- Include SEs and N for every regression table and in figure notes.
- Report exact p-values and bootstrap implementation details.
- Report cluster counts and discuss small-cluster inference (50 clusters is borderline but acceptable; CR2/wild bootstrap is appropriate—report results both ways).

3. IDENTIFICATION STRATEGY
- Credibility: The identification strategy—staggered state adoption, using never-treated as controls and CS-DiD estimator—is appropriate. The working-age restriction is a sensible attempt to reduce outcome dilution. The use of long pre-period (1999–2017) is a strength.
- Key assumptions: The paper discusses parallel trends, no-anticipation, and shows event-study pre-trends for 1999–2017. But a major limitation is the 2018–2019 gap immediately preceding the first treatment year (2020). The authors note this repeatedly. This gap weakens the ability to detect near-term pre-trend deviations and is a nontrivial threat to identification. The authors must:
  - Attempt to fill the 2018–2019 gap using alternative data access (retry CDC WONDER API; use the WONDER web interface for manual queries; request NCHS restricted files if necessary). The paper repeatedly mentions the API was unavailable “at the time of construction.” That should be resolved before submission if possible. If the authors cannot fill the gap, they must:
    - Provide additional robustness results that reduce dependence on the immediate pre-period—e.g., alternative event-study weighting that emphasizes longer-run pre-trends; sensitivity analysis showing parallel trends persist in many subwindows; and show that treated and control trends are similar in the most recent available pre-period (e.g., 2014–2017).
    - Provide placebo interventions placed in 2018 or 2019 in never-treated states to probe whether similar pre-post dynamics would be spuriously detected.
- Placebo tests and robustness: The paper implements placebo outcomes (cancer and heart disease), suppression sensitivity, Vermont classification sensitivity, cohort heterogeneity, COVID controls/exclusion, and HonestDiD. Those are appropriate and comprehensive. Still:
  - Report placebo regression tables with full inference and sample sizes.
  - Provide a multiple-testing correction or at least a discussion of multiple cohorts/coefficients (because the paper highlights a single significant cohort estimate at p = 0.044 for 2023 adopters).
  - For HonestDiD, fully document choices (range of M-bar used, smoothness bounds), and make the code/data to reproduce the sensitivity figures available.
- Do the conclusions follow? The paper is cautious and mostly avoids overclaiming. The conclusion that there is no detectable short-run mortality effect is reasonable given the reported estimates and their uncertainty. The caution on biological lag is appropriate. However, the paper should more explicitly state the limits of inference: the design gives ITT estimates at state-year level for working-age populations and is still underpowered to detect small-to-moderate effects on the treated subpopulation given dilution and short post period.

4. LITERATURE (missing references and suggestions)
The manuscript cites many key works (Callaway & Sant’Anna 2021, Goodman-Bacon 2021, Sun & Abraham 2021, Rambachan & Roth 2023, Bertrand et al. 2004) but I recommend adding the following important references and briefly explain why each matters to this paper. I include suggested BibTeX entries.

- Synthetic control / single-unit methods—this is a useful complementary method for early adopters (e.g., Colorado). Abadie et al. provide the foundational paper.
  - Why relevant: Synthetic control is a natural complementary approach for early or prominent adopters with longer post periods (Colorado) and can provide an alternative robustness check where the staggered design may be weak.
  - BibTeX:
  @article{Abadie2010,
    author = {Abadie, Alberto and Diamond, Alexis and Hainmueller, Jens},
    title = {Synthetic Control Methods for Comparative Case Studies: Estimating the Effect of California's Tobacco Control Program},
    journal = {Journal of the American Statistical Association},
    year = {2010},
    volume = {105},
    pages = {493--505}
  }

- RDD and local regression references (if the authors discuss RDD methods or bandwidth sensitivity in general methodological framing). Even if RDD is not used here, cite Imbens & Lemieux and Lee & Lemieux:
  - Why relevant: Standard references for discontinuity/bandwidth tests—cites useful for methods appendix and for readers needing RDD comparisons.
  - BibTeX:
  @article{Imbens2008,
    author = {Imbens, Guido W. and Lemieux, Thomas},
    title = {Regression Discontinuity Designs: A Guide to Practice},
    journal = {Journal of Econometrics},
    year = {2008},
    volume = {142},
    pages = {615--635}
  }
  @article{Lee2010,
    author = {Lee, David S. and Lemieux, Thomas},
    title = {Regression Discontinuity Designs in Economics},
    journal = {Journal of Economic Literature},
    year = {2010},
    volume = {48},
    pages = {281--355}
  }

- Borusyak & Jaravel (and Borusyak, Jaravel & Spiess) on two-way FE revisited (the paper cites Borusyak 2024 but ensure the correct reference and year):
  - Why relevant: Additional theoretical treatments on TWFE bias and alternative estimators help contextualize why CS-DiD is used.
  - BibTeX (example):
  @article{Borusyak2021,
    author = {Borusyak, Kirill and Jaravel, Xavier},
    title = {Revisiting Event Study Designs},
    journal = {Econometrica},
    year = {2021},
    volume = {89},
    pages = {LCCI--LCCI}
  }
  (If a different Borusyak et al. paper is intended, include the proper bibliographic information in your references.)

- Parallel trends sensitivity and Falsification literature (other relevant robustness methods beyond Rambachan):
  - Why relevant: Methods like fake-treatment dates, permutation inference, and other approaches complement HonestDiD.
  - Example BibTeX for placebo/permutation inference (Bertrand et al. already cited), but include Conley & Taber for inference with small number of treated clusters if relevant.

- Health economics / policy literature on insulin/copay changes and intermediate outcomes—include any recent empirical papers that analyze copay caps or insulin affordability using claims or survey data, in addition to Keating 2024 and Figinski 2024 cited in the text. If these are unpublished or working papers, add them with working-paper citations.

If any of the above are already in the references file you omitted, ensure correct citation entries. Provide more engagement with the literature on time to effect for mortality outcomes (the DCCT/EDIC references are excellent; consider also citing paper(s) that document lags between policy and mortality in other health contexts).

5. WRITING QUALITY (CRITICAL)
Overall the manuscript is well organized and uses paragraphs rather than bullets for major sections. However, to meet top-journal standards, the prose and narrative flow need polishing.

a) Prose vs bullets: The paper complies—major sections are paragraphs. Data and robustness lists employ bullet-like enumerations in some places (acceptable), but ensure any critical conceptual text remains in paragraph form.

b) Narrative flow:
- The Introduction is long and contains motivation, methods, and summary results; with some trimming it could be more concise and punchier. The “hook” is clear (insulin unaffordability and state copay caps), but the early paragraphs could place the policy urgency and the main contribution tighter: e.g., "Prior all-ages analyses are mechanically diluted; restricting to 25–64 increases treated share from ~3% to ~15–20% and makes detection more feasible."
- Later sections sometimes repeat the same point (data gap 2018–2019, Vermont suppression, dilution) in many places; consolidate the discussion of limitations into a focused subsection.

c) Sentence quality:
- The prose is generally clear, but occasionally reads as defensive (repeatedly stating code integrity fixes, which are important, but keep concise). Use active voice where possible. Put key insights at paragraph openings.

d) Accessibility:
- The econometric choices are explained adequately for an economics audience, but an intelligent non-expert may struggle with technical terms (e.g., “HonestDiD smoothness/FLCI approach”). Add brief intuitions for what these sensitivity methods do and what assumptions they relax.
- When reporting magnitudes, place them in context early: e.g., “mean working-age mortality = 13.8 per 100,000; the CS-DiD ATT = 0.92 (CI [-0.54, 2.38]) which is X% of mean” — the paper does some of that, but ensure consistency across the main tables/figures.

e) Figures/Tables:
- Ensure figure and table captions are self-contained: a reader should be able to understand what is plotted, what estimator was used, and sample size without flipping back to text. For event-study plots, add number of cohorts and treated states per bin in a small table below the figure.
- Table notes need to be explicit on inference methods (cluster-robust, CR2, wild bootstrap) and how p-values were constructed.

6. CONSTRUCTIVE SUGGESTIONS (to strengthen the contribution)
If the paper is to be accepted at a top journal it needs to do a few additional analyses, clarify documentation, and strengthen the narrative. Below are suggestions in order of priority:

High priority (must do or strongly justify not doing):
- Fill the 2018–2019 gap if possible. The inability to observe the two years immediately before the first treatment year is a material identification concern. Try the following:
  - Re-run data extraction on CDC WONDER (both API and web interface) and include code and queries in the replication archive.
  - If the API remains down, manually download those years via the web tool (or request NCHS data).
  - If impossible, provide enhanced sensitivity analysis demonstrating stability of trends in several pre-period windows that end in 2017 (e.g., 2010–2017, 2014–2017) and discuss why the 2018–2019 gap is unlikely to bias the result (but this will be a weaker alternative).
- Make replication materials complete and reproducible: include the data extraction scripts, code used for Callaway–Sant’Anna, HonestDiD, and all robustness checks. The paper notes a GitHub repository—ensure it contains the full replication package (raw data or instructions, processed data, and code).
- Provide a table of group-time ATTs and cohort sample sizes (exactly which states appear in each cohort/time cell), and include the weights used by CS-DiD for aggregation. This helps readers evaluate which cohorts drive results.
- For inference: present both asymptotic clustered SEs and small-sample corrections (CR2/wild bootstrap) side-by-side for main tables. Provide exact bootstrap details (replications, seed).

Medium priority (should strengthen paper):
- Add a complementary synthetic-control analysis for the earliest adopter(s) (e.g., Colorado) where pre-period length is long and the policy was fully implemented earlier; this provides an alternative view of treatment effects for at least one case study.
- Provide micro-level evidence (if possible) or cite existing work showing that copay caps increase utilization among commercial populations (Keating 2024 is cited). If possible, show intermediate outcomes (insulin fills, ED visits for DKA, hospitalizations) using publicly available data or state-level claim aggregates as evidence that the policy affected intermediates even if mortality did not change.
- Expand the cohort-heterogeneity analysis: is there evidence that states with lower caps (more generous) have larger ATTs? The paper reports heterogeneity by cap amount but with small Ns in subgroups; present effect sizes with CIs and discuss power.
- Perform multiple-testing adjustments when discussing cohort-specific significant results. The 2023 cohort result at p = 0.044 should be presented cautiously and adjusted for the number of cohorts/posterior tests.

Lower priority (polish and presentation):
- Provide a short table that translates population-level ATT into implied ATT for the treated subgroup across plausible s values (this is partly in the dilution table but ensure clear presentation and interpretation).
- Improve figure typography and ensure accessibility (colorblind palettes, larger fonts).
- Clarify Maine/Kentucky/Oklahoma cohort composition and any outlier states.

7. OVERALL ASSESSMENT
- Key strengths:
  - Timely and policy-relevant research question.
  - Appropriate modern econometric tools for staggered adoption (Callaway & Sant’Anna, Sun & Abraham), and multiple robustness checks (Bacon decomposition, HonestDiD, placebo outcomes).
  - Thoughtful conceptual discussion of outcome dilution and the biological lag.
  - Sensible and transparent discussion of limitations (2018–2019 gap, Vermont suppression, COVID noise).

- Critical weaknesses:
  - The 2018–2019 data gap directly before the first treatment year is a nontrivial threat to the parallel trends assessment; it must be remedied or mitigated convincingly.
  - Replication and bibliographic files are incomplete (references.bib not included in the source provided). For a top journal, full reproducibility is required.
  - Some tables/figures are externalized; ensure all axis labels, Ns, and SEs/CIs appear and that every coefficient has inference reported. I could not verify all tables in the provided source.
  - The power discussion is helpful, but the paper remains underpowered to detect small-to-moderate effects on the treated subgroup; this must be clearly emphasized throughout and limitations must not be downplayed.
  - The manuscript needs more precise documentation of bootstrap and small-sample inference methods and should include sensitivity to alternative control-group definitions (never-treated only vs. never + not-yet-treated).

8. SPECIFIC SUGGESTIONS FOR IMPROVEMENT (short checklist)
- Attempt to include 2018–2019 working-age mortality data (CDC WONDER) and re-run main analyses. If not possible, expand sensitivity analyses and justify why omission is unlikely to bias results.
- Include full bibliography (.bib) with correct and complete citations.
- Ensure every regression/table includes SEs (or CIs), exact p-values, N, and number of clusters.
- Provide group-time ATTs and the aggregation weights used by CS-DiD in an appendix table.
- Add a synthetic-control analysis for Colorado (and possibly another early adopter).
- Provide intermediate-outcome evidence (insulin fills, DKA ED visits) if possible or at least expand discussion linking observed changes in intermediate outcomes (Keating 2024) to possible mortality lag.
- Provide replication materials (data extraction scripts and cleaned data, or explicit instructions for access) in the GitHub repository and reference the exact commit/DOI used for the submission.
- Clarify HonestDiD implementation details and justify choices for M-bar and smoothness bounds.

DECISION: MAJOR REVISION

(If the authors address the data-gap, fully document inference, include missing references and replication materials, and add a synthetic-control or intermediate-outcome analysis, the paper could become a strong candidate for revision and possible publication.)